, Volume 27, Issue 5, pp 285-296
Date: 04 Jun 2010

Castration-refractory prostate cancer: New drugs in the pipeline

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naïve or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.